(UTHR) United Therapeutics - Ratings and Ratios
Inhaled Solution, Injection, Tablets, Dry Powder, Gene Therapy
UTHR EPS (Earnings per Share)
UTHR Revenue
Description: UTHR United Therapeutics
United Therapeutics Corporation is a biotechnology company that develops and commercializes products for chronic and life-threatening diseases. The companys product portfolio includes treatments for pulmonary arterial hypertension (PAH) such as Tyvaso DPI, Tyvaso, Remodulin, Orenitram, and Adcirca, as well as Unituxin for high-risk neuroblastoma. The companys pipeline includes RemoPro, Ralinepag, Aurora-GT gene therapy, and Nebulized Tyvaso for idiopathic pulmonary fibrosis.
From a business perspective, United Therapeutics has established partnerships with DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc. to develop new products and technologies, including a semi-disposable system for subcutaneous delivery of treprostinil and the Dreamboat device. The companys commitment to research and development is evident in its diverse pipeline, which includes gene therapy and xenografts, indicating a focus on innovative and potentially groundbreaking treatments.
Key Performance Indicators (KPIs) for United Therapeutics include revenue growth, driven by the sales of its PAH treatments and Unituxin. The companys ability to maintain a strong market presence in a competitive biotechnology industry is crucial. Other important KPIs include the progression of its pipeline products, particularly Aurora-GT and Ralinepag, through clinical trials and regulatory approvals. The companys return on equity (RoE) of 19.33% indicates a strong ability to generate profits from shareholder equity. Additionally, the companys low forward P/E ratio of 11.04 compared to its peers may indicate undervaluation, presenting a potential investment opportunity.
The companys product diversification and robust pipeline suggest a strategy focused on addressing unmet medical needs while driving growth. With a market capitalization of $13.5 billion, United Therapeutics has a significant presence in the biotechnology sector. Its commitment to developing innovative treatments, including gene therapy, positions the company for potential long-term success.
UTHR Stock Overview
| Market Cap in USD | 17,932m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1999-06-17 |
UTHR Stock Ratings
| Growth Rating | 40.8% |
| Fundamental | 89.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -0.72% |
| Analyst Rating | 4.0 of 5 |
UTHR Dividends
Currently no dividends paidUTHR Growth Ratios
| Growth Correlation 3m | 87.2% |
| Growth Correlation 12m | -57.7% |
| Growth Correlation 5y | 90% |
| CAGR 5y | 23.15% |
| CAGR/Max DD 3y | 0.70 |
| CAGR/Mean DD 3y | 1.50 |
| Sharpe Ratio 12m | -0.02 |
| Alpha | 3.39 |
| Beta | 0.625 |
| Volatility | 39.94% |
| Current Volume | 626.4k |
| Average Volume 20d | 651.7k |
| Stop Loss | 392.4 (-3.1%) |
| Signal | 0.59 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.24b TTM) > 0 and > 6% of Revenue (6% = 184.7m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 0.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 107.2% (prev 106.5%; Δ 0.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 1.37b > Net Income 1.24b (YES >=105%, WARN >=100%) |
| Net Debt (-1.59b) to EBITDA (1.66b) ratio: -0.96 <= 3.0 (WARN <= 3.5) |
| Current Ratio 7.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (48.3m) change vs 12m ago 1.68% (target <= -2.0% for YES) |
| Gross Margin 88.98% (prev 88.85%; Δ 0.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.07% (prev 38.92%; Δ 3.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 52.11 (EBITDA TTM 1.66b / Interest Expense TTM 31.4m) >= 6 (WARN >= 3) |
Altman Z'' 18.71
| (A) 0.42 = (Total Current Assets 3.83b - Total Current Liabilities 527.1m) / Total Assets 7.91b |
| (B) 0.99 = Retained Earnings (Balance) 7.85b / Total Assets 7.91b |
| warn (B) unusual magnitude: 0.99 — check mapping/units |
| (C) 0.22 = EBIT TTM 1.64b / Avg Total Assets 7.32b |
| (D) 10.70 = Book Value of Equity 7.85b / Total Liabilities 734.4m |
| Total Rating: 18.71 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.66
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 6.86% = 3.43 |
| 3. FCF Margin 34.80% = 7.50 |
| 4. Debt/Equity 0.10 = 2.49 |
| 5. Debt/Ebitda 0.44 = 2.35 |
| 6. ROIC - WACC 10.51% = 12.50 |
| 7. RoE 18.73% = 1.56 |
| 8. Rev. Trend 97.19% = 4.86 |
| 9. Rev. CAGR 17.21% = 2.15 |
| 10. EPS Trend 71.97% = 1.80 |
| 11. EPS CAGR 10.14% = 1.01 |
What is the price of UTHR shares?
Over the past week, the price has changed by +2.64%, over one month by +29.79%, over three months by +40.36% and over the past year by +17.40%.
Is United Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UTHR is around 418.11 USD . This means that UTHR is currently overvalued and has a potential downside of 3.23%.
Is UTHR a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the UTHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 466.8 | 15.3% |
| Analysts Target Price | 466.8 | 15.3% |
| ValueRay Target Price | 464.2 | 14.6% |
Last update: 2025-09-11 04:52
UTHR Fundamental Data Overview
CCE Cash And Equivalents = 3.05b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 15.4641
P/E Forward = 14.1243
P/S = 5.8263
P/B = 2.5458
P/EG = 1.4347
Beta = 0.619
Revenue TTM = 3.08b USD
EBIT TTM = 1.64b USD
EBITDA TTM = 1.66b USD
Long Term Debt = 207.3m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 527.1m USD (from totalCurrentLiabilities, last quarter)
Debt = 734.4m USD (Calculated: Short Term 527.1m + Long Term 207.3m)
Net Debt = -1.59b USD (from netDebt column, last quarter)
Enterprise Value = 15.62b USD (17.93b + Debt 734.4m - CCE 3.05b)
Interest Coverage Ratio = 52.11 (Ebit TTM 1.64b / Interest Expense TTM 31.4m)
FCF Yield = 6.86% (FCF TTM 1.07b / Enterprise Value 15.62b)
FCF Margin = 34.80% (FCF TTM 1.07b / Revenue TTM 3.08b)
Net Margin = 40.36% (Net Income TTM 1.24b / Revenue TTM 3.08b)
Gross Margin = 88.98% ((Revenue TTM 3.08b - Cost of Revenue TTM 339.1m) / Revenue TTM)
Tobins Q-Ratio = 1.99 (Enterprise Value 15.62b / Book Value Of Equity 7.85b)
Interest Expense / Debt = 0.99% (Interest Expense 7.30m / Debt 734.4m)
Taxrate = 22.35% (343.9m / 1.54b)
NOPAT = 1.27b (EBIT 1.64b * (1 - 22.35%))
Current Ratio = 7.26 (Total Current Assets 3.83b / Total Current Liabilities 527.1m)
Debt / Equity = 0.10 (Debt 734.4m / last Quarter total Stockholder Equity 7.17b)
Debt / EBITDA = 0.44 (Net Debt -1.59b / EBITDA 1.66b)
Debt / FCF = 0.69 (Debt 734.4m / FCF TTM 1.07b)
Total Stockholder Equity = 6.63b (last 4 quarters mean)
RoA = 15.71% (Net Income 1.24b, Total Assets 7.91b )
RoE = 18.73% (Net Income TTM 1.24b / Total Stockholder Equity 6.63b)
RoCE = 23.93% (Ebit 1.64b / (Equity 6.63b + L.T.Debt 207.3m))
RoIC = 18.53% (NOPAT 1.27b / Invested Capital 6.86b)
WACC = 8.02% (E(17.93b)/V(18.67b) * Re(8.32%)) + (D(734.4m)/V(18.67b) * Rd(0.99%) * (1-Tc(0.22)))
Shares Correlation 3-Years: -24.62 | Cagr: -0.07%
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 79.98% ; FCFE base≈993.8m ; Y1≈1.18b ; Y5≈1.83b
Fair Price DCF = 657.8 (DCF Value 29.75b / Shares Outstanding 45.2m; 5y FCF grow 19.75% → 3.0% )
Revenue Correlation: 97.19 | Revenue CAGR: 17.21%
Rev Growth-of-Growth: -4.81
EPS Correlation: 71.97 | EPS CAGR: 10.14%
EPS Growth-of-Growth: -7.91
Additional Sources for UTHR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle